The signalling cascade from initial stimulus to downstream effector — and where therapeutic intervention is possible at each node.
Lymphocyte trafficking to the intestinal mucosa is governed by integrin-mediated adhesion between circulating lymphocytes and gut vascular endothelium. The alpha4beta7 integrin heterodimer, expressed on gut-homing lymphocyte subsets, binds selectively to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), expressed predominantly on intestinal lamina propria venules and Peyer's patch high endothelial venules. This interaction, along with CCR9-CCL25 chemokine axis signalling, directs lymphocyte migration specifically to the gastrointestinal tract. In inflammatory bowel disease (IBD), dysregulated recruitment of pathogenic lymphocytes into the intestinal mucosa perpetuates chronic mucosal inflammation.
Vedolizumab, a humanised anti-alpha4beta7 monoclonal antibody, blocks the interaction between alpha4beta7 integrin and MAdCAM-1 with high selectivity for the gut. Unlike natalizumab (which targets the alpha4 subunit shared between alpha4beta7 and alpha4beta1, the latter mediating CNS lymphocyte trafficking via VCAM-1), vedolizumab does not impair CNS immune surveillance and carries no association with progressive multifocal leukoencephalopathy (PML). This gut-selective mechanism of action positions vedolizumab as a preferred choice in patients where systemic immunosuppression poses concern, or where prior anti-TNF therapy has failed.
Clinical trial data from the GEMINI programme established vedolizumab efficacy in both ulcerative colitis and Crohn's disease, with a characteristically slower onset of action compared to anti-TNF agents — particularly in Crohn's disease — attributed to the time required for existing mucosal lymphocyte populations to turnover. Vedolizumab is available in both intravenous (8-weekly maintenance) and subcutaneous (2-weekly maintenance) formulations, the latter following initial IV induction. The VARSITY trial demonstrated superiority of vedolizumab over adalimumab for clinical remission and mucosal healing in UC, informing positioning within the IBD treatment algorithm.
Upstream blockade vs downstream blockade — understanding the distinction is critical for treatment selection and sequencing.
Clinically actionable insights for treatment selection and sequencing
Lymphocyte trafficking to the intestinal mucosa is governed by integrin-mediated adhesion between circulating lymphocytes and gut vascular endothelium.
The alpha4beta7 integrin heterodimer, expressed on gut-homing lymphocyte subsets, binds selectively to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), expressed predominantly on intestinal lamina propria venules and Peyer's patch high endothelial venules.
This interaction, along with CCR9-CCL25 chemokine axis signalling, directs lymphocyte migration specifically to the gastrointestinal tract.
In inflammatory bowel disease (IBD), dysregulated recruitment of pathogenic lymphocytes into the intestinal mucosa perpetuates chronic mucosal inflammation.
Guidelines, trials, clinical briefs, podcasts and CPD connected to this pathway.
Get Gastroenterology Drug Science updates, related trials and education resources in your ClinicaliQ preferences.
Complete the reflective questions and self-assessment to claim your CPD certificate for this molecular mechanism hub.
Go to CPD Centre →